## Hyejin Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4733906/publications.pdf Version: 2024-02-01



HVEIIN CHOL

#	Article	IF	CITATIONS
1	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell Reports, 2020, 30, 755-770.e6.	2.9	65
2	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
3	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 2019, 27, 806-819.e5.	2.9	51
4	Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor. Neoplasia, 2017, 19, 55-64.	2.3	45
5	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS ONE, 2015, 10, e0129123.	1.1	17
6	Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model. Cell Reports, 2015, 10, 1187-1201.	2.9	137
7	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 2015, 527, 472-476.	13.7	1,498
8	Suppression of miRNA-708 by Polycomb Group Promotes Metastases by Calcium-Induced Cell Migration. Cancer Cell, 2013, 23, 63-76.	7.7	135
9	Bone Marrow–Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1. Cancer Discovery, 2013, 3, 578-589.	7.7	113
10	Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Research, 2012, 72, 1384-1394.	0.4	261
11	Discovery of Novel Human Breast Cancer MicroRNAs from Deep Sequencing Data by Analysis of Pri-MicroRNA Secondary Structures. PLoS ONE, 2011, 6, e16403.	1.1	29
12	Pulsatile MEK Inhibition Improves Anti-Tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0